This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Van Gompel, J. J. Articles by Chen, H. Search for Related Content PubMed PubMed Citation Articles by Van Gompel, J. J. Articles by Chen, H.

Departments of ¹ Surgery and ² Medicine, University of Wisconsin Medical School and ³ University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin

Requests for reprints: Herbert Chen, Department of Surgery, University of Wisconsin Medical School, H4/750 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792. Phone: 608-263-1387; Fax: 608-263-7652. E-mail: chen{at}surgery.wisc.edu

Neuroendocrine tumors, such as carcinoids, are highly metastatic neoplasms that secrete bioactive hormones resulting in carcinoid syndrome. Few curative treatments exist outside of surgical resection. We have previously shown that activation of the Raf-1 signaling pathway can suppress hormone production in carcinoid tumor cells. In this study, we investigated a novel treatment for carcinoid tumor cell growth based on pharmacologic Raf-1 activation using the compound ZM336372. Treatment of carcinoid tumor cells with ZM336372 resulted in progressive phosphorylation of Raf-1, mitogen-activated protein kinase 1/2, and extracellular signal–regulated kinase 1/2. Importantly, exposure to ZM336372 resulted in a significant reduction of bioactive hormone levels as well as the transcription factor, human achaete-scute homologue-1 in carcinoid tumor cells. Furthermore, treatment with ZM336372 led to a marked suppression of cellular proliferation and induction of the cell cycle inhibitors p21 and p18. In summary, ZM336372 targets both proliferation and palliative issues associated with carcinoid tumor cells, and therefore, warrants further investigation as a possible therapeutic strategy for patients with carcinoid tumors.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: J. Van Gompel and M. Kunnimalaiyaan contributed equally to this work.

⁴ Unpublished data.

Received 12/14/04; revised 3/ 1/05; accepted 4/12/05.